Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
|
J Clin Oncol
|
2014
|
9.86
|
2
|
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
|
Clin Cancer Res
|
2013
|
3.48
|
3
|
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.
|
Cancer Cell
|
2014
|
2.71
|
4
|
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
|
Nat Rev Clin Oncol
|
2013
|
2.64
|
5
|
PD-1 as a potential target in cancer therapy.
|
Cancer Med
|
2013
|
1.98
|
6
|
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
|
J Leukoc Biol
|
2013
|
1.90
|
7
|
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
|
Trends Mol Med
|
2014
|
1.59
|
8
|
The role of B7 family molecules in hematologic malignancy.
|
Blood
|
2012
|
1.47
|
9
|
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
|
Semin Oncol
|
2015
|
1.45
|
10
|
Trial watch: Monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2013
|
1.41
|
11
|
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
|
Clin Cancer Res
|
2013
|
1.39
|
12
|
Immunotherapy in the treatment of non-small cell lung cancer.
|
Lung Cancer
|
2014
|
1.35
|
13
|
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
|
Clin Cancer Res
|
2014
|
1.33
|
14
|
Control of the immune response by pro-angiogenic factors.
|
Front Oncol
|
2014
|
1.26
|
15
|
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2016
|
1.24
|
16
|
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
|
J Clin Oncol
|
2016
|
1.24
|
17
|
Targeted therapy for non-small-cell lung cancer: past, present and future.
|
Expert Rev Anticancer Ther
|
2013
|
1.22
|
18
|
Nivolumab in NSCLC: latest evidence and clinical potential.
|
Ther Adv Med Oncol
|
2015
|
1.21
|
19
|
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
|
Sci Rep
|
2015
|
1.18
|
20
|
Molecular pathways and therapeutic targets in lung cancer.
|
Oncotarget
|
2014
|
1.16
|
21
|
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
|
Front Oncol
|
2015
|
1.15
|
22
|
New immunotherapies targeting the PD-1 pathway.
|
Trends Pharmacol Sci
|
2015
|
1.02
|
23
|
Clinical impact of checkpoint inhibitors as novel cancer therapies.
|
Drugs
|
2014
|
0.99
|
24
|
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
|
Front Immunol
|
2015
|
0.98
|
25
|
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
|
J Thorac Oncol
|
2015
|
0.97
|
26
|
Advances in immunotherapy for treatment of lung cancer.
|
Cancer Biol Med
|
2015
|
0.95
|
27
|
Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
|
Br J Clin Pharmacol
|
2013
|
0.94
|
28
|
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
|
Cancer Manag Res
|
2014
|
0.94
|
29
|
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
|
Front Oncol
|
2015
|
0.92
|
30
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
31
|
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
|
Lancet Oncol
|
2016
|
0.90
|
32
|
New strategies in immunotherapy for non-small cell lung cancer.
|
Transl Lung Cancer Res
|
2015
|
0.89
|
33
|
Updates in the management of brain metastases.
|
Neuro Oncol
|
2016
|
0.88
|
34
|
Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
|
J Thorac Oncol
|
2015
|
0.87
|
35
|
Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer?
|
Semin Oncol
|
2013
|
0.87
|
36
|
Immune checkpoint inhibitors in NSCLC.
|
Curr Treat Options Oncol
|
2014
|
0.85
|
37
|
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.
|
Onco Targets Ther
|
2013
|
0.85
|
38
|
Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.
|
Cancer
|
2014
|
0.84
|
39
|
Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
|
Onco Targets Ther
|
2016
|
0.82
|
40
|
Immunotherapy in lung cancer.
|
Transl Lung Cancer Res
|
2014
|
0.82
|
41
|
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
|
Oncologist
|
2015
|
0.81
|
42
|
Immunotherapy in lung cancer.
|
Transl Lung Cancer Res
|
2014
|
0.80
|
43
|
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy.
|
Med Oncol
|
2014
|
0.80
|
44
|
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.
|
Expert Rev Mol Diagn
|
2016
|
0.80
|
45
|
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
|
Transl Lung Cancer Res
|
2015
|
0.80
|
46
|
The changing landscape of phase I trials in oncology.
|
Nat Rev Clin Oncol
|
2015
|
0.79
|
47
|
New targeted treatments for non-small-cell lung cancer - role of nivolumab.
|
Biologics
|
2016
|
0.79
|
48
|
Cellular and molecular immunology of lung cancer: therapeutic implications.
|
Expert Rev Clin Immunol
|
2014
|
0.79
|
49
|
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.
|
Transl Lung Cancer Res
|
2014
|
0.78
|
50
|
Promising targets and current clinical trials in metastatic squamous cell lung cancer.
|
Front Oncol
|
2014
|
0.78
|
51
|
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
|
Transl Lung Cancer Res
|
2015
|
0.78
|
52
|
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
|
Semin Immunol
|
2016
|
0.78
|
53
|
Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting.
|
Ann Transl Med
|
2016
|
0.77
|
54
|
Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.
|
Eur J Cardiothorac Surg
|
2015
|
0.77
|
55
|
Targeted immunotherapy for non-small cell lung cancer.
|
World J Clin Oncol
|
2014
|
0.75
|
56
|
Embracing rejection: Immunologic trends in brain metastasis.
|
Oncoimmunology
|
2016
|
0.75
|
57
|
What does the future hold for immunotherapy in cancer?
|
Ann Transl Med
|
2016
|
0.75
|
58
|
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?
|
Transl Lung Cancer Res
|
2016
|
0.75
|
59
|
Adding fuel to the fire: immunogenic intensification.
|
Hum Vaccin Immunother
|
2014
|
0.75
|
60
|
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations.
|
Onco Targets Ther
|
2016
|
0.75
|